0000000001143685

AUTHOR

Stefania De Lorenzo

showing 1 related works from this author

Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma

2021

<b><i>Introduction:</i></b> Cabozantinib has been approved by the European Medicine Agency (EMA) for hepatocellular carcinoma (HCC) previously treated with sorafenib. Cabozantinib is also being tested in combination with immune checkpoint inhibitors in the frontline setting. Real-life clinical data of cabozantinib for HCC are still lacking. Moreover, the prognostic factors for HCC treated with cabozantinib have not been investigated. <b><i>Methods:</i></b> We evaluated clinical data and outcome of HCC patients who received cabozantinib in the legal context of named patient use in Italy. <b><i>Results:</i></b> Ninety-six…

OncologySorafenibmedicine.medical_specialtyCabozantinibHepatocellular carcinomaContext (language use)chemistry.chemical_compoundInternal medicineCabozantinib; Hepatocellular carcinoma; Outcome; Sorafenib; Tyrosine kinase inhibitorsmedicineAdverse effectRC254-282OutcomeTyrosine kinase inhibitorsSettore MED/12 - GastroenterologiaOriginal PaperHepatologyPerformance statusbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensCabozantinibSorafenibmedicine.diseaseClinical trialOncologychemistryHepatocellular carcinomaLiver functionbusinessmedicine.drug
researchProduct